ErbB receptors: Directing key signaling networks throughout life

被引:501
作者
Holbro, T [1 ]
Hynes, NE [1 ]
机构
[1] Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland
关键词
D O I
10.1146/annurev.pharmtox.44.101802.121440
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The epidermal growth factor (EGF)-related peptides bind the ErbB receptors, inducing the formation of different homo- and heterodimers. Receptor dimerization promotes activation of the intrinsic kinase, leading to phosphorylation of specific tyrosines located in the ErbB's cytoplasmic region. These phosphorylated residues serve as docking sites for a variety of signaling molecules whose recruitment stimulates intracellular signaling cascades, which ultimately control diverse genetic programs. Particular ligand-receptor complexes have essential roles in embryonic development as well as in the adult. Finally, ErbB receptors are being pursued as therapeutic targets because aberrant ErbB activity has been observed in many human cancers. In this review, we discuss these data in more detail, illustrating the importance of tightly regulated ErbB signaling throughout life.
引用
收藏
页码:195 / 217
页数:25
相关论文
共 149 条
[111]  
SAUTER G, 1993, CANCER RES, V53, P2199
[112]   Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2 -: Potential mechanism for trastuzumab-induced cardiotoxicity [J].
Sawyer, DB ;
Zuppinger, C ;
Miller, TA ;
Eppenberger, HM ;
Suter, TM .
CIRCULATION, 2002, 105 (13) :1551-1554
[113]   Cell Signaling by Receptor Tyrosine Kinases [J].
Lemmon, Mark A. ;
Schlessinger, Joseph .
CELL, 2010, 141 (07) :1117-1134
[114]   A thousand and one roles for the Drosophila EGF receptor [J].
Schweitzer, R ;
Shilo, BZ .
TRENDS IN GENETICS, 1997, 13 (05) :191-196
[115]   The ADAMs family of metalloproteases: multidomain proteins with multiple functions [J].
Seals, DF ;
Courtneidge, SA .
GENES & DEVELOPMENT, 2003, 17 (01) :7-30
[116]   Cardiac dysfunction in the trastuzumab clinical trials experience [J].
Seidman, A ;
Hudis, C ;
Pierri, MK ;
Shak, S ;
Paton, V ;
Ashby, M ;
Murphy, M ;
Stewart, SJ ;
Keefe, D .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1215-1221
[117]   A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor [J].
Sibilia, M ;
Steinbach, JP ;
Stingl, L ;
Aguzzi, A ;
Wagner, EF .
EMBO JOURNAL, 1998, 17 (03) :719-731
[118]   STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER [J].
SLAMON, DJ ;
GODOLPHIN, W ;
JONES, LA ;
HOLT, JA ;
WONG, SG ;
KEITH, DE ;
LEVIN, WJ ;
STUART, SG ;
UDOVE, J ;
ULLRICH, A ;
PRESS, MF .
SCIENCE, 1989, 244 (4905) :707-712
[119]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792
[120]   HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].
SLAMON, DJ ;
CLARK, GM ;
WONG, SG ;
LEVIN, WJ ;
ULLRICH, A ;
MCGUIRE, WL .
SCIENCE, 1987, 235 (4785) :177-182